Candel Therapeutics, Inc. (CADL) Stock Ticker
Market factors today
Unlock the full CADL picture
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
CADL stock facts
| Ticker symbol | CADL |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $807.4M |
| CEO | Paul-Peter Tak |
| Employees | 55 |
| Headquarters | Needham, MA, US |
| IPO date | 2021-07-27 |
| Website | www.candeltx.com |
What you can see for CADL on Tickr
Live CADL price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CADL report.
Rankings
FAQ
What is the ticker symbol for Candel Therapeutics, Inc.?
The ticker symbol for Candel Therapeutics, Inc. is CADL, listed on the NASDAQ Global Market.
What is CADL?
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials…